Avid Bioservices Long Term Debt

Avid Bioservices (CDMO) currently reports a long-term debt of $200M as of October 2024. That compares with $190M in the prior-year period — up 5.2% year over year. Use the charts on this page to explore Avid Bioservices's long-term debt history and peer comparisons.

Avid Bioservices's long-term debt increased from $190M to $200M — a 5.2% year-over-year increase (period ending October 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Avid Bioservices reported $200M in long-term debt as of October 2024. That compares with $190M in the prior-year period — up 5.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $200M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Avid Bioservices, and consider following CDMO for alerts when major investors trade the stock.

Avid Bioservices is classified in the Healthcare sector. On long-term debt, it currently shows $200M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CDMO with unrelated industries.